News
12-08-2011, 04:10 AM
Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who received the combination therapy with placebo...
More... (http://www.medicalnewstoday.com/releases/238843.php)
More... (http://www.medicalnewstoday.com/releases/238843.php)